Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	OrganiGram	Albireo Pharma	Akouos	Atreca	Intercept Pharmaceuticals
Symbol	NASDAQ:OGI	NASDAQ:ALBO	NASDAQ:AKUS	NASDAQ:BCEL	NASDAQ:ICPT
Price Information
Current Price	$2.77	$31.94	$14.51	$11.48	$22.14
52 Week Range	Hold	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.6	1.5	1.6	1.7	2.2
Analysis Score	4.2	3.5	3.4	3.5	4.1
Community Score	3.0	2.5	2.5	2.7	3.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	1.7	1.7	3.3
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Hold	Buy	Buy	Buy	Hold
Consensus Price Target	$4.60	$72.00	$31.67	$29.00	$50.70
% Upside from Price Target	66.02% upside	125.42% upside	118.24% upside	152.61% upside	128.98% upside
Trade Information
Market Cap	$643.39 million	$610.50 million	$499.17 million	$422.82 million	$730.97 million
Beta	0.3	1.62	N/A	0.08	1.85
Average Volume	24,492,986	172,677	220,302	261,110	1,107,927
Sales & Book Value
Annual Revenue	$64.61 million	$9.64 million	N/A	N/A	$252 million
Price / Sales	9.96	63.33	N/A	N/A	2.90
Cashflow	$0.03 per share	N/A	N/A	N/A	N/A
Price / Cash	101.50	N/A	N/A	N/A	N/A
Book Value	$1.04 per share	$7.34 per share	N/A	$6.68 per share	$1.57 per share
Price / Book	2.66	4.35	N/A	N/A	14.10
Profitability
Net Income	$-101,290,000.00	$-62,720,000.00	N/A	$-67,480,000.00	$-344,680,000.00
EPS	($0.08)	($5.04)	N/A	($4.26)	($10.89)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-207.26%	-751.53%	N/A	N/A	-106.64%
Return on Equity (ROE)	-10.00%	-71.22%	N/A	-43.21%	-1,973.10%
Return on Assets (ROA)	-7.14%	-42.91%	N/A	-40.98%	-48.51%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.17%	0.04%	N/A	N/A	N/A
Current Ratio	2.66%	13.52%	37.39%	28.48%	3.44%
Quick Ratio	3.39%	13.51%	37.39%	28.48%	3.44%
Ownership Information
Institutional Ownership Percentage	10.84%	85.65%	88.70%	69.64%	85.77%
Insider Ownership Percentage	N/A	5.00%	N/A	9.90%	23.70%
Miscellaneous
Employees	516	90	54	130	498
Shares Outstanding	232.27 million	19.11 million	34.40 million	36.83 million	33.02 million
Next Earnings Date	4/13/2021 (Confirmed)	5/6/2021 (Estimated)	7/5/2021 (Estimated)	5/13/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Small Cap Stock Intercept Pharmaceuticals, Inc. (ICPT) is a Overweight – Analysts marketingsentinel.com - April 12 at 3:01 PM
	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average Rating of "Hold" from Brokerages americanbankingnews.com - April 4 at 4:36 AM
	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is Worth a Shot if You’re a Risk-Capital Investor marketingsentinel.com - March 29 at 2:04 PM
	Intercept Pharmaceuticals Stock Is Believed To Be Possible Value Trap finance.yahoo.com - March 28 at 1:57 AM
	Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue? finance.yahoo.com - March 27 at 2:48 PM
	What Did We Learn From Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Trading? stocksregister.com - March 26 at 1:42 PM
	Intercept Pharmaceuticals Inc. [ICPT] Stock trading around $24.88 per share: What’s Next? dbtnews.com - March 26 at 8:42 AM
	Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Price Up 7.2% americanbankingnews.com - March 25 at 11:37 AM
	3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall Street finance.yahoo.com - March 23 at 3:52 AM
	Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Rating Upgraded by HC Wainwright americanbankingnews.com - March 18 at 10:12 AM
	Intercept Pharmaceuticals (NASDAQ:ICPT) Raised to Neutral at HC Wainwright marketbeat.com - March 18 at 8:35 AM
	Biotechnology Stocks Giving Back Ground After Yesterday's Rally nasdaq.com - March 16 at 5:02 PM
	Monday 3/15 Insider Buying Report: ICPT, DBX nasdaq.com - March 15 at 3:56 PM
	Intercept Announces Departure of Chief Financial Officer finance.yahoo.com - March 10 at 8:09 AM
	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Just Reported Earnings, And Analysts Cut Their Target Price nasdaq.com - February 28 at 1:15 PM
	Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2020 Results - Earnings Call Transcript seekingalpha.com - February 26 at 6:44 PM
	Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss finance.yahoo.com - February 26 at 1:44 PM
	Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues ... apnews.com - February 25 at 9:53 AM
	Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Misses Revenue Estimates nasdaq.com - February 25 at 9:53 AM
	Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update finance.yahoo.com - February 25 at 9:53 AM
	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Long Term Investor Alert: Investigation of Potential Wrongdoing sbwire.com - February 24 at 1:44 PM
	Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors marketwatch.com - February 23 at 9:16 AM
	Intercept to Present at Upcoming Investor Conferences finance.yahoo.com - February 19 at 10:26 AM
	Investigation announced for Long-Term Investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) openpr.com - February 19 at 5:26 AM
	Avadel Pharmaceuticals Appoints Richard Kim As CCO; Says He Will Lead Launch Of Once-Nightly FT218, Pending Regulatory Approval benzinga.com - February 17 at 3:05 PM
	Intercept Appoints Linda Richardson as Chief Commercial Officer markets.businessinsider.com - February 17 at 9:03 AM

Date	Company	Brokerage	Action
4/8/2021	OrganiGram	BMO Capital Markets	Upgrade
3/16/2021	OrganiGram	Stifel Nicolaus	Boost Price Target
3/12/2021	OrganiGram	CIBC	Boost Price Target
3/12/2021	OrganiGram	Raymond James	Boost Price Target
3/11/2021	OrganiGram	Cantor Fitzgerald	Reiterated Rating
3/11/2021	OrganiGram	Alliance Global Partners	Reiterated Rating
1/12/2021	OrganiGram	Canaccord Genuity	Downgrade
8/10/2020	OrganiGram	Jefferies Financial Group	Reiterated Rating
7/21/2020	OrganiGram	Pi Financial	Reiterated Rating
7/21/2020	OrganiGram	AltaCorp Capital	Downgrade
7/21/2020	OrganiGram	Oppenheimer	Reiterated Rating
3/8/2021	Albireo Pharma	Piper Sandler	Boost Price Target
3/1/2021	Albireo Pharma	Robert W. Baird	Reiterated Rating
12/18/2020	Albireo Pharma	HC Wainwright	Boost Price Target
11/19/2020	Albireo Pharma	Wedbush	Reiterated Rating
9/10/2020	Albireo Pharma	Cowen	Boost Price Target
9/8/2020	Albireo Pharma	Needham & Company LLC	Boost Price Target
8/10/2020	Albireo Pharma	William Blair	Reiterated Rating
3/30/2021	Akouos	Bank of America	Downgrade
7/21/2020	Akouos	BTIG Research	Initiated Coverage
9/4/2019	Atreca	Roth Capital	Initiated Coverage
8/20/2019	Atreca	Brookline Capital Management	Reiterated Rating
7/15/2019	Atreca	Evercore ISI	Initiated Coverage
3/1/2021	Intercept Pharmaceuticals	B. Riley	Lower Price Target
3/1/2021	Intercept Pharmaceuticals	Chardan Capital	Lower Price Target
11/10/2020	Intercept Pharmaceuticals	Royal Bank of Canada	Lower Price Target
11/10/2020	Intercept Pharmaceuticals	Credit Suisse Group	Lower Price Target
11/10/2020	Intercept Pharmaceuticals	SVB Leerink	Lower Price Target

(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources